"Gastric cancer treatment is rapidly transforming into a highly individualized journey, meticulously tailored to the unique biological and molecular profile of each tumor, alongside patient-specific factors and disease stage."
The journey of treating gastric cancer has entered a new era of precision medicine, moving away from a one-size-fits-all approach towards highly individualized treatment strategies. This paradigm shift is driven by a deeper understanding of the tumor’s biology and molecular characteristics, the precise stage of the cancer, and a comprehensive evaluation of the patient’s overall health and specific circumstances. Consequently, a sophisticated array of treatment modalities is now employed, ranging from surgical interventions to conventional chemotherapy, radiation therapy, and increasingly, highly targeted therapies and immunotherapies. Healthcare professionals are tasked with navigating this complex and evolving landscape, making informed decisions that balance the latest evidence with patient-specific considerations, potential toxicities, and overarching treatment goals.
The Ascendancy of Biomarker-Driven Therapy in Advanced Gastric Cancer
The management of advanced gastric cancer is increasingly dictated by the assessment of its molecular and biomarker characteristics. Identifying specific markers within the tumor has become paramount in guiding therapeutic decisions. Key among these are HER2 expression, programmed death-ligand 1 (PD-L1) expression, the presence of microsatellite instability (MSI) and/or mismatch repair (MMR) deficiency, and the expression of Claudin 18.2 (CLDN18.2). These biomarkers are not merely descriptive; they are active participants in shaping treatment pathways for patients with advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinomas.
The European treatment guidance for advanced or metastasized gastric or gastroesophageal junction cancer, as outlined by the ESMO (European Society for Medical Oncology) Consensus Conference, exemplifies this biomarker-centric approach. These guidelines delineate distinct, biomarker-defined treatment pathways, assigning patients to specific therapeutic subgroups based on their HER2 status, PD-L1 expression levels, MSI status, and CLDN18.2 expression. This sophisticated stratification ensures that systemic therapies are administered to patients most likely to benefit, maximizing efficacy and minimizing unnecessary exposure to treatments that may prove ineffective.
The integration of biomarker information into systemic treatment decisions for advanced or metastatic gastric and GEJ adenocarcinomas is supported by a growing body of evidence. However, this information must be considered within a broader clinical context. Factors such as local and international regulatory approvals, institutional capacities, and the availability of specific diagnostic and therapeutic resources are crucial components of this decision-making process. Thus, while biomarkers provide a critical foundation, they are integrated with practical considerations to ensure the most effective and feasible treatment plan for each individual.
The Expanding Role of HER2-Directed Therapy
The significance of HER2 (Human Epidermal growth factor Receptor 2) as a therapeutic target in gastric cancer has been firmly established. Trastuzumab, a monoclonal antibody that targets the HER2 protein, has become a cornerstone of treatment for patients with HER2-positive gastric cancer. It is utilized both as a single agent and in combination with various chemotherapy regimens, offering different clinical scenarios where its efficacy can be leveraged. The decision to use trastuzumab as a standalone therapy or as part of a combination regimen depends on a nuanced evaluation of the patient’s disease, previous treatments, and overall health status.
Further advancements have seen the integration of immunotherapy with HER2-directed therapies. For instance, pembrolizumab, an immune checkpoint inhibitor, in combination with trastuzumab and a fluoropyrimidine- and platinum-containing chemotherapy, has shown promise for patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma. This combination therapy is contingent upon the tumor expressing PD-L1 with a Combined Positive Score (CPS) of 1 or greater, highlighting the synergistic potential of targeting both the tumor’s growth pathways and its immune evasion mechanisms.
Historically, the assessment of HER2 and PD-L1 expression has been performed as separate evaluations, with clinical decisions often made based on the findings of each biomarker in isolation. However, a more integrated approach, considering the interplay between these markers and other clinical factors, is increasingly recognized as beneficial for optimizing treatment outcomes.
Incorporating CLDN18.2 into the Treatment Arsenal
Claudin 18.2 (CLDN18.2) represents another critical biomarker that is gaining prominence in the treatment of gastric cancer. For patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma that expresses CLDN18.2, zolbetuximab-clzb has emerged as an approved treatment option. This targeted therapy, when administered in combination with fluoropyrimidine- and platinum-containing chemotherapy, offers a new avenue for patients who may not have benefited from previous treatment strategies.
The approval of zolbetuximab-clzb is accompanied by a companion diagnostic test designed to identify patients eligible for this therapy. This companion diagnostic is crucial for accurately assessing CLDN18.2 expression levels, ensuring that the treatment is administered to individuals whose tumors meet the specific biomarker threshold. The validation of appropriate testing methodologies and the establishment of precise expression thresholds are vital for the successful implementation of CLDN18.2-targeted therapies. This ensures that treatment decisions are precisely aligned with biomarker status and approved indications, maximizing the potential for therapeutic benefit.
The Evolving Role of Immunotherapy and MSI Status
Immune checkpoint inhibitors have revolutionized the treatment landscape for various cancers, and advanced gastric cancer is no exception. These therapies harness the patient’s own immune system to fight cancer cells, particularly in selected patients whose tumors exhibit high microsatellite instability (MSI-high) or mismatch repair deficiency (dMMR). Tumors with these characteristics are often more susceptible to the effects of immunotherapy.
PD-L1 expression also plays a significant role in guiding immunotherapy decisions. While some patients are selected based on MSI status alone, for others, PD-L1 expression, evaluated using specific scoring systems and thresholds, serves as a critical decision criterion. For example, ESMO treatment recommendations for advanced gastric and GEJ adenocarcinoma often incorporate the PD-L1 CPS to inform the use of certain immunotherapies.
It is important to recognize that biomarkers are not universally present in all gastric tumors. A proportion of tumors may not express these specific markers, or may express them at varying levels. Furthermore, a single tumor can express multiple biomarkers, necessitating a sophisticated, multidisciplinary approach to their interpretation. This integrated perspective is essential for making comprehensive and informed treatment decisions.
Reassessing and Reordering Treatment Strategies
The management of gastric cancer, particularly in its potentially curable stages, continues to emphasize a multidisciplinary evaluation that informs surgical interventions and perioperative approaches. However, for advanced disease, the selection of systemic therapy is increasingly dictated by these biomarker-defined subgroups. This dynamic approach necessitates a continuous reevaluation of treatment plans. Decisions should not be static, but rather revisited as new pathological findings, imaging results, molecular data, or clinical information becomes available. This iterative process ensures that treatment remains aligned with the most current understanding of the disease and the patient’s evolving condition.
For potentially curable gastric cancer, the primary treatment options involve surgical resection, often preceded by neoadjuvant therapy and followed by adjuvant systemic treatment. In contrast, advanced gastric cancer is primarily managed with systemic therapies. The choice of these therapies is a complex interplay of the patient’s disease characteristics, prior treatment history, overall health, and organ function.
Therefore, every patient encounter in the clinic presents an opportunity to re-examine the treatment plan. This review should incorporate the latest developments, including newly obtained pathology results, the most recent imaging studies, updated molecular profiling, and any pertinent clinical information. This proactive approach ensures that the treatment strategy remains optimal and responsive to the nuances of the individual patient’s journey.
Navigating Toxicity and Patient-Centric Factors
The intricate process of treatment selection in gastric cancer necessitates careful consideration of numerous patient-specific factors. Prior treatment history, individual patient preferences, compromised organ function, the presence of comorbidities, and age are all critical elements, particularly for older patients with a poor performance status. The potential toxicities associated with different treatment options must be meticulously weighed against their potential benefits. This includes evaluating the risk of drug interactions, the duration of treatment, and the patient’s capacity to manage side effects.
Effective supportive care is an indispensable component of gastric cancer management. This encompasses nutritional assessment, symptom control, and open, empathetic communication with patients and their families. These elements are vital throughout all phases of treatment, significantly influencing a patient’s ability to complete their therapy and maintain a good quality of life.
The Indispensable Role of Multidisciplinary Care
The increasing complexity of gastric cancer treatment underscores the critical importance of multidisciplinary collaboration. Regular meetings involving medical oncologists, surgeons, radiation oncologists, pathologists, radiologists, dietitians, and specialist nurses are instrumental in providing comprehensive and coordinated care. This integrated approach ensures that all aspects of the patient’s condition are considered, leading to more informed and holistic treatment decisions.
A crucial aspect of this multidisciplinary effort is the seamless coordination of pathology and molecular testing with treatment planning. Discussions within a multidisciplinary meeting (MDM) empower clinicians to systematically evaluate key factors influencing treatment decisions. These include the disease stage, detailed pathological findings, biomarker status, imaging results, previous treatment interventions, and a thorough understanding of patient-specific factors.
Future Directions in Gastric Cancer Treatment
The horizon of gastric cancer treatment is continuously expanding with ongoing investigations into novel therapeutic agents and modalities. ESMO’s research initiatives are at the forefront of exploring next-generation treatments, including targeted therapies, antibody-drug conjugates (ADCs), and cellular therapies. Promising avenues of research include treatments specifically targeting CLDN18.2 in gastric and GEJ cancers, as well as the development of ADCs and CAR-T cell therapies.
For healthcare professionals seeking the most current understanding of evidence supporting these promising therapies, along with information on health authority approvals and the required biomarker testing, consulting up-to-date clinical guidelines for the diagnosis and treatment of gastric cancer is essential. These guidelines serve as invaluable tools to support clinical decision-making, though they are intended to complement, not replace, clinical expertise and judgment.
Ultimately, personalized gastric cancer treatment is becoming increasingly intricate, demanding an individualized approach that meticulously considers the stage of the disease, the unique biological nature of the tumor, the patient’s specific clinical circumstances, and their personal treatment goals. This comprehensive, patient-centered strategy is paving the way for improved outcomes and enhanced quality of life for individuals battling gastric cancer.
